Company Profile

SHILPA MEDICARE LTD.

NSE : SHILPAMEDBSE : 530549ISIN CODE : INE790G01031Industry : Pharmaceuticals & DrugsHouse : Private
BSE266.451.3 (+0.49 % )
PREV CLOSE (Rs.) 265.15
OPEN PRICE (Rs.) 256.00
BID PRICE (QTY) 266.45 (260 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1106
TODAY'S LOW / HIGH (Rs.)256.00 276.60
52 WK LOW / HIGH (Rs.)255.2 546.95
NSE268.40 3.7 (+1.4 % )
PREV CLOSE(Rs.) 264.70
OPEN PRICE (Rs.) 266.50
BID PRICE (QTY) 268.40 (11 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 58260
TODAY'S LOW / HIGH(Rs.) 257.85 276.00
52 WK LOW / HIGH (Rs.)255.6 548.9

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 2.94263
Dividend Yield(%)
TTM EPS (Rs.)
P/E Ratio
Book Value (Rs.)
Face Value (Rs.)
MCap (Rs. in Mn)
Price/Earning (TTM)
Price/Sales (TTM)
Price/Book (MRQ)
PAT Margin (%) 17.91
ROCE (%) 13.00
Incorporation Year : 1987

Management Info :

Omprakash Inani - Chairman Vishnukant Bhutada - Managing Director

Registered Office :

Address : #12-6-214/a1,Hyderabad Road, ,
Raichur,
Karnataka-584135

Phone : 08532-238704

Website : www.vbshilpa.com

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
29Jul07-29-2019$Shilpa Medicare completes USFDA audit at Raichur API site Shilpa Medicare completes US

Shilpa Medicare has completed US Food and Drug Administration (USFDA) audit at its API site, Raichur between July 22, 2019 and July 26, 2019. The company has received Form 483 with 5 observations, with no repeat observations and any data integrity observations. The observations are mostly procedural in nature.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare has completed US Food and Drug Administration (..
29Jul07-29-2019$Shilpa Medicare informs about company updates Shilpa Medicare informs abou

Shilpa Medicare has informed that the Company has completed USFDA audit at its API site, Raichur between 22nd July 2019 and 26th July 2019. The Company has received Form 483 with 5 observations, with no repeat observations and any data integrity observations. The observations are mostly procedural in nature.

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare has informed that the Company has completed USF..
29Jul07-29-2019$Shilpa Medicare trades in green on the BSE Shilpa Medicare trades in gr

Shilpa Medicare is currently trading at Rs. 352.00, up by 0.05 points or 0.57% from its previous closing of Rs. 350.00 on the BSE.

The scrip opened at Rs. 346.15 and has touched a high and low of Rs. 352.00 and Rs. 346.00 respectively.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 546.95 on 14-Sep-2018 and a 52 week low of Rs. 328.05 on 02-Apr-2019.

Last one week high and low of the scrip stood at Rs. 356.00 and Rs. 334.90 respectively. The current market cap of the company is Rs. 2861.59 crore.

The promoters holding in the company stood at 53.80%, while Institutions and Non-Institutions held 26.59% and 19.60% respectively.

Shilpa Medicare has completed US Food and Drug Administration (USFDA) audit at its API site, Raichur between July 22, 2019 and July 26, 2019. The company has received Form 483 with 5 observations, with no repeat observations and any data integrity observations. The observations are mostly procedural in nature.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare is currently trading at Rs. 352.00, up by 0.05..
28May05-28-2019$Shilpa Medicare to foray into R&D activities of specific drug processes Shilpa Medicare to foray int

Shilpa Medicare has received approval to foray into the R&D activities of specific drug processes by roping prominent technocrats through a new subsidiary company incorporated as Sravathi Advance Process Technologies. The Board of Directors of the Company at its meeting held on May 27, 2019 has approved the same.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare has received approval to foray into the R&D..
28May05-28-2019$Shilpa Medicare informs about resignation of director Shilpa Medicare informs abou

Shilpa Medicare has informed that Namrata Bhutada (DIN: 05l336l4), Director of the Company, has submitted her resignation due to her personal reasons and the same has been accepted by the Board of Directors with effect from 27th May, 2019. She has been on the Board since 28th February, 2015.

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare has informed that Namrata Bhutada (DIN: 05l336l..
Financials More
Rs. in Millions
QTR Jun 19 ANNUAL 19
Net Profit261.041241.06
Gross Profit 316.97 1556
Operating Profit 424.711894.37
Net Sales 1545.776638.79
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Dr. Reddys Lab (BSE)
 2554.90 (1.77%)
M.Cap ( in Cr)
42440.42
Astrazeneca Pharma I (BSE)
 1774.20 (2.41%)
M.Cap ( in Cr)
4435.50
Jenburkt Pharma (BSE)
 451.90 (6.33%)
M.Cap ( in Cr)
207.39
Alkem Laboratories (BSE)
 1768.85 (1.27%)
M.Cap ( in Cr)
21149.26
Everest Organics (BSE)
 179.15 (11.97%)
M.Cap ( in Cr)
143.32
Shareholding Pattern More
PROMOTERS 53.8 %
NON-INSTITUTION 19.6 %
FI/BANKS/INSURANCE 0.12 %
MUTUAL FUNDS/UTI 0.06 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
F & O Quotes